Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Milgamma is a brand name for a range of pharmaceutical and dietary supplement products containing combinations of B vitamins—primarily benfotiamine (a fat-soluble derivative of vitamin B1), pyridoxine hydrochloride (vitamin B6), and in some formulations cyanocobalamin (vitamin B12). The main mechanism involves replenishing these essential micronutrients to treat or prevent neurological disorders caused by their deficiency. Benfotiamine is absorbed more efficiently than standard thiamine and is converted in the body to active vitamin B1. Pyridoxine supports nerve metabolism as vitamin B6. Cyanocobalamin provides vitamin B12 for nerve health. These combinations are used primarily for neuropathies and other neurological conditions associated with deficiencies in these vitamins[1][2][4][5][7][10]. Injectable forms may also contain lidocaine to reduce injection discomfort[5][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on milgamma.